Skip to main content

Table 3 Changes in CT-1 and hs-CRP levels of eligible patients before and after treatment

From: Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial

 

Baicalin (n = 166)

Placebo (n = 165)

Baseline

Post treatment

Baseline

Post treatment

CT-1

194.6 ± 42.3

42.9 ± 13.7 *

187.4 ± 39.1

128.4 ± 24.3 *#

hs-CRP

32.4 ± 2.3

1.64 ± 0.38 *

30.8 ± 2.7

3.9 ± 1.4 *#

  1. Values are mean ± SD. *p < 0.05 compared to baseline within the same group; #p < 0.05 compared at the same time point between two groups. CT-1 cardiotrophin-1, hs-CRP high-sensitivity C-reactive protein
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X